- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.11. | Journey Medical GAAP EPS of -$0.12 beats by $0.03, revenue of $14.63M beats by $0.24M | 1 | Seeking Alpha | ||
| 12.11. | Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights | 51 | GlobeNewswire (Europe) | U.S. FDA approved Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025... ► Artikel lesen | |
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 12.11. | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11. | FDA approves Journey Medical's Emrosi to treat inflammatory lesions of rosacea | - | PMLiVE | ||
| 05.11. | FDA approves Journey Medical's rosacea treatment Emrosi | 1 | Pharmaceutical Technology | ||
| 04.11. | Journey Medical, with FDA nod, won't stop believing it can establish new rosacea standard of care | 3 | FiercePharma | ||
| 04.11. | What's Going On With Journey Medical Stock Today? | 2 | Benzinga.com | ||
| 04.11. | Journey Medical: FDA Approves Emrosi For Treatment Of Inflammatory Lesions Of Rosacea | 1 | RTTNews | ||
| 04.11. | Journey Medical Corporation Announces U.S. FDA Approval of Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea | 111 | GlobeNewswire (Europe) | SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and... ► Artikel lesen | |
| 04.11. | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 03.10. | Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference | 2 | GlobeNewswire (USA) | ||
| 01.10. | PVG Asset Management Corp Purchases New Holdings in Journey Medical Co. (NASDAQ:DERM) | 2 | MarketBeat | ||
| 09.09. | Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference | 1 | GlobeNewswire (USA) | ||
| 06.09. | Lake Street starts Journey Medical with Buy, sets stock target on product launch | 1 | Investing.com | ||
| 04.09. | Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 2 | GlobeNewswire (USA) | ||
| 13.08. | Journey Medical Corporation (NASDAQ:DERM) Q2 2024 Earnings Call Transcript | 2 | Insider Monkey | ||
| 13.08. | Journey Medical holds steady with Buy rating on revenue beat | 2 | Investing.com | ||
| 13.08. | Earnings call: Journey Medical on track with solid Q2 results, DFD-29 launch | 2 | Investing.com | ||
| 12.08. | Journey Medical GAAP EPS of -$0.17 misses by $0.03, revenue of $14.85M beats by $0.97M | 1 | Seeking Alpha | ||
| 12.08. | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 23,630 | -0,17 % | Pfizer, BioNTech & Co: Trump-Ankündigung setzt Aktien unter Druck | Die Aktien von Impfstoff-Unternehmen stehen zum Wochenschluss deutlich unter Druck. Sowohl Moderna, als auch BioNTech, Pfizer und Novavax notieren im vorbörslichen US-Handel im Minus. Auch andere Pharmawerte... ► Artikel lesen | |
| GILEAD SCIENCES | 84,75 | +0,78 % | Gilead's Livdelzi Shows Sustained Efficacy, Long-Term Safety In PBC Management | FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% of participants with... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 432,65 | +1,05 % | VERTEX - Wie kurz sind die Beine politischer Börsen? | ||
| EYEPOINT PHARMACEUTICALS | 8,616 | +1,34 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 9,050 | -0,55 % | Astria TherapeuticS GAAP EPS of -$0.42 in-line | ||
| OPKO HEALTH | 1,508 | +0,27 % | Opko Health CEO Phillip Frost kauft Aktien im Wert von 161.980 US-Dollar | ||
| LIGAND PHARMACEUTICALS | 106,00 | 0,00 % | ROUNDUP: Ligand Pharmaceuticals Boosts FY24 Outlook | WASHINGTON (dpa-AFX) - While reporting financial results for the third quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) raised its core adjusted earnings and... ► Artikel lesen | |
| EXSCIENTIA | 4,520 | -1,74 % | XFRA 0RK: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEXSCIENTIA SP.ADRS... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 116,00 | +2,47 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract ... | Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S.Ziihera received accelerated approval based on results including a 52% objective response... ► Artikel lesen | |
| ROCKET LAB USA | 19,260 | +0,63 % | Is Rocket Lab Stock a Millionaire Maker? | ||
| ROYALTY PHARMA | 24,710 | -0,68 % | Dividendenbekanntmachungen (15.11.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 0,7 USD 0,6646 EUR ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0712 EUR AGCO CORPORATION US0010841023 0... ► Artikel lesen | |
| TG THERAPEUTICS | 29,920 | +1,15 % | TG Therapeutics, Inc.: TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500 | ||
| CATALYST PHARMACEUTICALS | 20,090 | +0,10 % | Vorstandsvorsitzender von Catalyst Pharmaceuticals verkauft Aktien im Wert von 3,1 Millionen US-Dollar | ||
| CATALENT | 55,81 | -0,27 % | Catalent-Direktorin Ryan Michelle R verkauft Aktien im Wert von 167.160 US-Dollar | ||
| CORBUS PHARMACEUTICALS | 15,100 | -1,31 % | Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Short Interest Down 13.5% in October |
JOURNEY MEDICAL CORPORATION gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 5,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.
